Home › PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy
 

Keywords :   


PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy

2014-12-29 01:59:52| drugdiscoveryonline Home Page

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)

Tags: treat begins rolling submission

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09This Week in Agribusiness, September 28, 2024
28.09This Week in Agribusiness, September 28, 2024
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 10
28.09Hurricane Isaac Wind Speed Probabilities Number 10
28.09Hurricane Isaac Public Advisory Number 10
More »